High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
- 1 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 70 (1), 143-149
- https://doi.org/10.1007/s12020-020-02388-0
Abstract
Purpose Treatment with dopamine agonists (DA) is highly effective in patients with prolactinomas. In selected patients, discontinuation of DA after several years of successful treatment is possible, however, hyperprolactinemia recurs in 60-80% of them. It is unclear what is the clinical significance of these recurrences and hence, whether or not reinitiation of therapy is necessary. Objectives To evaluate the recurrence rate in prolactinoma patients after DA withdrawal and the necessity to restart treatment. Methods Patients with >2 years of treatment with cabergoline (CBG) who achieved normoprolactinemia anda > 50% reduction in tumor size were included. DA dose was down titrated until withdrawal. Basal tumor size, as well as PRL and gonadal steroid levels were recorded at diagnosis, at withdrawal of DA and every 3-6 months for 1-3 years. Results Fifty patients were included (38 women, 34 macroprolactinomas). After withdrawal, 34 (68%) presented recurrence of hyperprolactinemia. PRL levels <5 ng/mL at the time of withdrawal predicted remission (sensitivity 76%, specificity of 63%). CBG was restarted in eight patients (23%) because of the presence of hypogonadism. CBG was withheld in the remaining 26, based on the following arguments: (1) premenopausal women without biochemical hypogonadism, (54%); (2) asymptomatic men under 65 without biochemical hypogonadism (19%); (3) asymptomatic postmenopausal women (19%); (4) asymptomatic men over 65 (8%). After a median follow-up of 30 months, no increase in PRL levels or tumor growth was documented. Conclusions Biochemical recurrence in prolactinomas is very frequent, however, in only a few of these patients reinitiation of DA is necessary.Keywords
This publication has 26 references indexed in Scilit:
- Dopamine agonists in prolactinomas: when to withdraw?Pituitary, 2020
- Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawalPituitary, 2017
- Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?Pituitary, 2016
- Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challengesJournal of Clinical Neuroscience, 2015
- Update on prolactinomas. Part 2: Treatment and management strategiesJournal of Clinical Neuroscience, 2015
- Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experiencePituitary, 2011
- Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2011
- Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapyNature Clinical Practice Endocrinology & Metabolism, 2006
- Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonistsActa Neuropathologica, 2005
- Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomasClinical Endocrinology, 2005